

WORLDWIDE APPROVAL

TIVICAY 50mg Tablets

Argentina	Ghana	Niger
Armenia	Guatemala	Nigeria
Aruba	Guinea	Oman
Australia	Guyana	Pakistan
Azerbaijan	Haiti	Panama
Bahrain	Honduras	Peru
Belarus	Hong Kong	Philippines
Bosnia and Herzegovina	Indonesia	Qatar
Botswana	Israel	Republic of Korea
Brazil	Jamaica	Russian Federation
Brunei Darussalam	Japan	Saudi Arabia
Burkina Faso	Jordan	Senegal
Cameroon	Kazakhstan	Serbia
Canada	Kenya	Sierra Leone
Central Africa Republic	Kuwait	Singapore
Chad	Kyrgyzstan	Suriname
Chile	Lebanon	Switzerland
China	Liberia	Taiwan
Colombia	Macau	Tanzania
Congo	Macedonia	Thailand
Costa Rica	Malawi	Togo
Cote d'Ivoire	Malaysia	Trinidad and Tobago
Curacao	Mali	Turkey
Democratic Republic of Congo	Mexico	Uganda
Dominican Republic	Moldova	Ukraine
Ecuador	Mongolia	United Arab Emirates
Egypt	Montenegro	United Kingdom
El Salvador	Morocco	United States of America
Ethiopia	Mozambique	Uruguay
European Union	Myanmar	Uzbekistan
Gabon	Namibia	Zambia
Georgia	New Zealand	Zimbabwe

- ✓ **"Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.**
- ✓ **Granted Marketing Authorisations may include limitations on the use of the product.**

This document was prepared on 24 November 2023 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.